Aerovate Therapeutics Net Worth
Aerovate Therapeutics Net Worth Breakdown | AVTE |
Aerovate Therapeutics Net Worth Analysis
Aerovate Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aerovate Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aerovate Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aerovate Therapeutics' net worth analysis. One common approach is to calculate Aerovate Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aerovate Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aerovate Therapeutics' net worth. This approach calculates the present value of Aerovate Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aerovate Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aerovate Therapeutics' net worth. This involves comparing Aerovate Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aerovate Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Aerovate Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aerovate Therapeutics' net worth research are outlined below:
| Aerovate Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Disposition of 2051 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 |
Aerovate Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aerovate Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aerovate Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Aerovate Therapeutics Target Price Consensus
Aerovate target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Aerovate Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Hold |
Most Aerovate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Aerovate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Aerovate Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAerovate Therapeutics Target Price Projection
Aerovate Therapeutics' current and average target prices are 2.58 and 2.33, respectively. The current price of Aerovate Therapeutics is the price at which Aerovate Therapeutics is currently trading. On the other hand, Aerovate Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Aerovate Therapeutics Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Aerovate Therapeutics Target Price
Know Aerovate Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aerovate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aerovate Therapeutics backward and forwards among themselves. Aerovate Therapeutics' institutional investor refers to the entity that pools money to purchase Aerovate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gsa Capital Partners Llp | 2024-09-30 | 413.8 K | Ikarian Capital, Llc | 2024-09-30 | 368 K | State Street Corp | 2024-09-30 | 367.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 334 K | Two Sigma Investments Llc | 2024-09-30 | 313.1 K | Geode Capital Management, Llc | 2024-09-30 | 291.9 K | Bank Of America Corp | 2024-09-30 | 261 K | Citigroup Inc | 2024-09-30 | 233.4 K | Millennium Management Llc | 2024-09-30 | 196.6 K | Ra Capital Management, Llc | 2024-09-30 | 9.2 M | Sofinnova Ventures | 2024-09-30 | 3.8 M |
Follow Aerovate Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.59 M.Market Cap |
|
Project Aerovate Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.56) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.79) | (0.75) |
When accessing Aerovate Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aerovate Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aerovate Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Aerovate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerovate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aerovate Therapeutics' management manipulating its earnings.
Evaluate Aerovate Therapeutics' management efficiency
Aerovate Therapeutics has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.56. In addition to that, Return On Capital Employed is expected to decline to -0.7. At present, Aerovate Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3.1 M, whereas Total Current Assets are forecasted to decline to about 96.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.74 | 2.51 | |
| Tangible Book Value Per Share | 3.74 | 2.51 | |
| Enterprise Value Over EBITDA | (8.10) | (7.70) | |
| Price Book Value Ratio | 4.90 | 5.14 | |
| Enterprise Value Multiple | (8.10) | (7.70) | |
| Price Fair Value | 4.90 | 5.14 | |
| Enterprise Value | 626.2 M | 407.8 M |
Understanding the operational decisions made by Aerovate Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aerovate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aerovate Therapeutics Corporate Filings
| 13th of January 2025 Other Reports | ViewVerify | |
| 3rd of December 2024 Other Reports | ViewVerify | |
| 25th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Aerovate Therapeutics Earnings Estimation Breakdown
The calculation of Aerovate Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aerovate Therapeutics is estimated to be -0.63 with the future projection ranging from a low of -0.6525 to a high of -0.6075. Please be aware that this consensus of annual earnings estimates for Aerovate Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.65 Lowest | Expected EPS | -0.61 Highest |
Aerovate Therapeutics Earnings Projection Consensus
Suppose the current estimates of Aerovate Therapeutics' value are higher than the current market price of the Aerovate Therapeutics stock. In this case, investors may conclude that Aerovate Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aerovate Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 3 | 87.27% | -0.56 | -0.63 | -3.17 |
Aerovate Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Aerovate Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Aerovate Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Aerovate Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Aerovate Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Aerovate Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Aerovate Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Aerovate Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Aerovate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-14 | 2024-09-30 | -0.17 | -0.56 | -0.39 | 229 | ||
2024-08-12 | 2024-06-30 | -0.83 | -0.86 | -0.03 | 3 | ||
2024-05-13 | 2024-03-31 | -0.76 | -0.83 | -0.07 | 9 | ||
2024-03-25 | 2023-12-31 | -0.71 | -0.74 | -0.03 | 4 | ||
2023-11-13 | 2023-09-30 | -0.69 | -0.71 | -0.02 | 2 | ||
2023-08-14 | 2023-06-30 | -0.7 | -0.76 | -0.06 | 8 | ||
2023-05-15 | 2023-03-31 | -0.6 | -0.67 | -0.07 | 11 | ||
2023-03-29 | 2022-12-31 | -0.62 | -0.61 | 0.01 | 1 | ||
2022-11-14 | 2022-09-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2022-08-15 | 2022-06-30 | -0.45 | -0.49 | -0.04 | 8 | ||
2022-05-16 | 2022-03-31 | -0.28 | -0.45 | -0.17 | 60 | ||
2022-03-30 | 2021-12-31 | -0.31 | -0.35 | -0.04 | 12 | ||
2021-11-15 | 2021-09-30 | -0.26 | -0.26 | 0.0 | 0 | ||
2021-08-16 | 2021-06-30 | -0.16 | -23.8 | -23.64 | 14775 | ||
2021-06-30 | 2021-03-31 | 0 | -12.77 | -12.77 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -3.7007 | -3.7007 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -1.9147 | -1.9147 | 0 |
Aerovate Therapeutics Corporate Management
| Timothy Pigot | VP Commercial | Profile | |
| Sanjeev Khindri | Executive Development | Profile | |
| Benjamin Dake | President, Founder | Profile | |
| Timothy MBA | CEO Director | Profile | |
| Marinus Verwijs | Chief Officer | Profile | |
| Stephen Yu | Senior Quality | Profile | |
| BSc MD | Senior Development | Profile |
Already Invested in Aerovate Therapeutics?
The danger of trading Aerovate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aerovate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aerovate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aerovate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.